First-in-human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors

por Stein, Mark N., Bertino, Joseph, Kaufman, Howard L., Mayer, Tina M., Moss, Rebecca A., Silk, Ann W., Chan, Nancy, Malhotra, Jyoti, Rodriguez, Lorna, Aisner, Joseph, Aiken, Robert, Haffty, Bruce G., DiPaola, Robert S., Saunders, Tracie, Zloza, Andrew, Damare, Sherri, Beckett, Yasmeen, Yu, Bangning, Najmi, Saltanat, Gabel, Christian, Dickerson, Siobhan, Zheng, Ling, El-Deiry, Wafik S., Allen, Joshua E., Stogniew, Martin, Oster, Wolfgang, Mehnert, Janice M.
Publicado en Clin Cancer Res (2017)

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

por Stein, Mark N., Malhotra, Jyoti, Tarapore, Rohinton S., Malhotra, Usha, Silk, Ann W., Chan, Nancy, Rodriguez, Lorna, Aisner, Joseph, Aiken, Robert D., Mayer, Tina, Haffty, Bruce G., Newman, Jenna H., Aspromonte, Salvatore M., Bommareddy, Praveen K., Estupinian, Ricardo, Chesson, Charles B., Sadimin, Evita T., Li, Shengguo, Medina, Daniel J., Saunders, Tracie, Frankel, Melissa, Kareddula, Aparna, Damare, Sherrie, Wesolowsky, Elayne, Gabel, Christian, El-Deiry, Wafik S., Prabhu, Varun V., Allen, Joshua E., Stogniew, Martin, Oster, Wolfgang, Bertino, Joseph R., Libutti, Steven K., Mehnert, Janice M., Zloza, Andrew
Publicado en J Immunother Cancer (2019)